Damora Therapeutics, Inc.
Data quality: 83%
DMRA
Nasdaq
Manufacturing
Chemicals
$25.74
▲
$0.14
(0.55%)
Mkt Cap: 1.55 B
Price
$25.74
Mkt Cap
1.55 B
Day Range
$24.95 — $26.99
52-Week Range
$2.06 — $38.33
Volume
113,844
Open $24.96
50D / 200D Avg
$26.22
1.84% below
50D / 200D Avg
$14.99
71.66% above
Quick Summary
Key Takeaways
Negative free cash flow of -6.73 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-2213.49%
Below sector avg (-51.02%)
ROIC-1737.56%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio3.73
Interest Coverage-180.70
Valuation
PE (TTM)
-7.40
Below sector avg (-1.98)
P/B Ratio193.86
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (44 peers)
Peer Comparison
vs Manufacturing sector median (44 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -7.4 | -2.0 |
| P/B | 193.9 | 5.1 |
| ROE % | -2213.5 | -51.0 |
| Net Margin % | — | -150.2 |
| Rev Growth 5Y % | — | 9.3 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -209.84 M |
| ROE | -2213.49% | ROA | -1718.09% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -6.73 M |
| ROIC | -1737.56% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3.73 |
| Interest Coverage | -180.70 | Asset Turnover | N/A |
| Working Capital | 7.16 M | Tangible Book Value | 8.01 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -7.40 | Forward P/E | N/A |
| P/B Ratio | 193.86 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -0.43% | ||
| Market Cap | 1.55 B | Enterprise Value | 1.54 B |
| Per Share | |||
| EPS (Diluted TTM) | 3.98 | Revenue / Share | N/A |
| FCF / Share | -0.11 | OCF / Share | -0.11 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 3.21% |
| SBC-Adj. FCF | -7.92 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -209.84 M | -21.44 M | -38.35 M | -61.62 M | -51.75 M |
| EPS (Diluted) | 3.98 | -18.53 | -1.44 | -2.43 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -210.87 M | -22.26 M | -39.91 M | -61.21 M | -52.23 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 26.88 M | 6.40 M | 23.77 M | 48.21 M | 38.49 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 1.17 M | 844,000.0 | 1.69 M | 722,000.0 | 156,000.0 |
| Income Tax | 50,000.0 | 41,000.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 260.53 M | 17.13 M | 38.23 M | 73.19 M | 122.22 M |
| Total Liabilities | 20.15 M | 1.30 M | 5.90 M | 11.44 M | 4.99 M |
| Shareholders' Equity | 240.38 M | 15.83 M | 32.33 M | 61.75 M | 117.22 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 257.62 M | 14.18 M | 21.47 M | 32.79 M | 62.56 M |
| Current Assets | 260.42 M | 16.84 M | 36.77 M | 63.91 M | 110.10 M |
| Current Liabilities | 20.07 M | 1.20 M | 5.83 M | 11.11 M | 4.54 M |
{"event":"ticker_viewed","properties":{"ticker":"DMRA","listing_kind":"stock","pathname":"/stocks/dmra","exchange":"Nasdaq","country":"US"}}